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Background: Sarcomatoid carcinomas (SCs) are rare tumors that may 
arise in the lung, accounting for 0.4% of non–small-cell lung cancers; 
the prognosis is poor. Only few retrospective small-size series have 
studied the efficacy of chemotherapy (CT) for metastatic SC.
Methods: Multicenter study of patients with advanced or metastatic 
SC who received first-line CT. Clinical characteristics at baseline, 
response to first-line CT (Response Evaluation Criteria in Solid 
Tumors version 1.1), progression-free survival (PFS), and overall 
survival (OS) were retrospectively collected.
Results: Ninety-seven patients were included. Median age was 62 
(54–72) years. The majority of patients were men (70%), white (84%), 
and smokers (84%). Overall, 73% of patients received first-line plati-
num-based CT. At first tumor evaluation, 69% of patients experienced 
progression, 31% had disease control, and 16.5% had partial response. 
Partial response was observed in 20% of patients receiving platinum-
based CT, and in none of those receiving non–platinum-based CT (p 
= 0.018). Median PFS was 2.0 months (confidence interval [CI] 95%: 
1.8–2.3). PFS was not statistically different between patients receiv-
ing or not receiving a platinum-based CT. Median OS was 6.3 months 
(CI 95%: 4.7–7.8). There was a trend toward better OS for patients 
treated with platinum-based CT (7.0 months [CI 95%: 4.9–9.0] ver-
sus 5.3 months [CI 95%: 2.8–7.6]; p = 0.096). In multivariate analy-
sis, disease control at first evaluation (hazard ratio = 0.38 [CI 95%: 
0.21–0.59]) and at platinum-based CT (hazard ratio = 0.92 [CI 95%: 
0.85–0.99]) was associated with better OS.
Conclusion: SC is associated with poor prognosis and high rate of 
resistance to conventional first-line CT. New therapeutic strategies 
are needed, based on better knowledge of the carcinogenesis of SC.
Key Words: Non–small-cell lung carcinoma, Sarcomatoid carci-
noma, Prognosis, Chemotherapy.
(J Thorac Oncol. 2013;8: 1574–1577)
Sarcomatoid carcinomas (SCs) are rare tumors that may arise in the lung, where they account for approximately 
0.4% of non–small-cell lung cancers (NSCLC).1 SCs have 
been reported to be associated with a poor prognosis, as com-
pared with other NSCLCs. In the Surveillance Epidemiology 
Endpoints Results database, SC histology was associated 
with significantly shorter overall survival (OS) (hazard ratio 
[HR] = 1.60; confidence interval [CI] 95%: 1.35–3.06; 
p = 0.004) in early-stage NSCLC.1 For metastatic disease, 
median OS was 3 months in the Surveillance Epidemiology 
Endpoints Results database,1 and 5 to 8.5 months in five retro-
spective series collectively including less than 50 patients.2–6 
Limited information is available about the efficacy of chemo-
therapy (CT) for SC. We have recently shown that SC his-
tological type was independently associated with a 7.5 risk 
of progression during a first-line treatment by platinum-based 
CT in a retrospective cohort of 178 NSCLCs.2 Finally, a 58% 
to 85% disease progression rate after first-line CT was also 
reported in two small-size retrospective series.3,4 In this arti-
cle, we conducted a multicentric retrospective study to focus 
on types of CT and outcome in a large cohort of patients with 
histologically proven advanced or metastatic SC.
PATIENTS AND METHODS
Patients were screened in the archive of chest and 
pathology departments from nine medical centers and from a 
French National Cancer Institute–sponsored network for rare 
thoracic tumors. From January 1999 to September 2012, all 
consecutive patients with pathologically proven SC presenting 
at an advanced or metastatic stage, who received a first-line 
CT, were included in this analysis. All the pathological speci-
mens were locally reviewed according to the World Health 
Organization’s classification 2004. After reviewing, 18 cases 
were overruled out by the pathologists. At the time of diag-
nosis, baseline clinical data were collected. Response to CT 
was evaluated every two to three cycles and classified as rec-
ommended by Response Evaluation Criteria in Solid Tumors 
criteria.7 Computed tomography scans were retrospectively 
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analyzed for 84 patients. Data were collected from medical 
records for the remaining 13 cases. Best response was reported. 
End point was defined as September 1, 2012. According to 
national guidelines, each patient signed a research approval 
form.
RESULTS
Clinical and Anatomic Characteristics
From 1999 to 2012, 97 consecutive patients with 
pathologically confirmed SC, treated with first-line CT, 
were included in this study. Most frequent subtypes were 
pleomorphic (61%), spindle-cell (13.5%), and giant-cell 
carinoma (9.5%) (Supplementary Table 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A477). Median 
age was 62 (54–72) years. The majority of patients were 
men (70%), white (84%), and smokers (84%). Patients were 
often symptomatic (84%). Most frequent symptoms were 
cough (35%), chest pain (31%), and weight loss (30%). 
Performance status (PS) was 0 to 1 in 72% of cases. At base-
line assessment, all patients had an advanced or metastatic 
disease. Among them, 42 presented with metastatic had 
relapse after previous surgery. Sixteen percent of patients 
had stage III disease and were not eligible for chemoradio-
therapy because of tumor volume. Eighty-four percent had 
stage IV disease. Metastatic locations were similar to that 
observed in NSCLCs overall, that is the adrenal glands, the 
lung, the pleura, the brain, the bone, or the liver but also 
included unusual anatomic sites, such as the subdiaphrag-
matic nodes, the peritoneum, the kidney, and the pancreas. 
Sixty-two percent of patients had more than two metastatic 
locations (Supplementary Table 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A477).
FIGURE 1.  Waterfall plot of individual progression-free survival according to chemotherapy regimen. 5FU, fluorouracil.
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First-Line CT
First-line treatment was platinum-based CT regimen 
for 71 patients (73%) and a non–platinum-based CT for 26 
patients (27%). Third-generation drug was associated with 
platinum in 61 patients (63%). Main regimens for monother-
apy were gemcitabine, erlotinib, pemetrexed, docetaxel, pacli-
taxel, and vinorelbine. Patients who received platinum-based 
CT had a better PS (0–1) than those who did not received 
platinum-based CT (93% versus 23%; p < 0.0001).
Outcome
Patients received a median number of three cycles of CT 
(interquartile range, 2–4). First assessment of response was 
performed after a median of two cycles of CT (interquartile 
range, 1–3). At first evaluation, 69% of patients showed pro-
gressive disease and 31% disease control (DC), with 16.5% 
of partial responses (PRs) and 14.5% of stable disease. PR 
was observed in 20% of patients receiving a platinum-based 
versus none of those receiving non–platinum-based regimen 
(p = 0.018). Response rates did not differ between treatment 
regimens. The best response was always that observed at the 
first evaluation. Age, sex, ethnicity, tobacco status, symptoms, 
PS, histological subtypes, stage, and previous surgery did not 
significantly correlate with response rate.
Median progression-free survival (PFS) was 2.0 months 
(CI 95%: 1.8–2.3). At univariate analysis, no factor including 
age, sex, ethnicity, tobacco status, symptoms, PS, histological 
subtypes, stage, and previous surgery significantly influenced 
PFS. PFS was not statistically different in patients treated with 
or without platinum-based CT. According to individual PFS 
(Fig. 1), some patients had a better PFS with platinum plus 
gemcitabine or platinum plus paclitaxel regimen than other 
combinations. At multivariate analysis, no factor was associ-
ated with better PFS.
Median OS was 6.3 months (CI 95%: 4.7–7.8). There 
was a trend toward a better OS for patients treated with 
platinum-based CT (7.0 months; CI 95%: 4.9–9.0) versus 
others (5.3 months; CI 95%: 2.8–7.6; p = 0.096). At uni-
variate analysis, DC was the only factor associated with a 
significantly better OS (Table 1). At multivariate analysis, 
DC at first evaluation (HR = 0.38; CI 95%: 0.21–0.59) and 
 platinum-based CT (HR = 0.92; CI 95%: 0.85–0.99) and non-
smoking status (HR = 0.92; CI 95%: 0.85–0.99) were associ-
ated with prolonged OS.
DISCUSSION
This study is the first to report on a large cohort of 
patients (n = 97) with advanced or metastatic lung SC. Our 
findings indicate that these tumors were associated with a 
poor outcome and resistance to conventional first-line CT. 
Progression rate was 69% at first evaluation. Median PFS and 
OS were 2.0 months (CI 95%: 1.8–2.3) and 6.3 months (CI 
95%: 4.7–7.6), respectively. Similar results with high rates 
of progression ranging from 58% to 85% under first-line CT 
have been previously reported in smaller retrospective stud-
ies.3,4 These rates are higher and the survival is shorter than 
those usually observed for other NSCLC histological sub-
types: progression rate to first-line CT was 38%, median PFS 
was 4.3 months, and median OS was 8.9 months in the analy-
sis of three randomized studies including 984 patients with 
NSCLC of other histological subtypes than SC.8
In our analysis, progression rates were not different 
among patients treated with or without platinum-based CT 
and among patients treated with different platinum-based 
CT regimens. The drugs used were heterogeneous because of 
the time of patient recruitment, inherent to the rarity of SC. 
Nevertheles, almost 90% of patients treated with platinum-
based CT received a third-generation drug. Interestingly, PR 
was observed only in patients who received platinum-based 
CT. This could suggest that platinum-based CT might have a 
higher efficacy even if this observation did not translate into 
a longer PFS (p = 0.301). Nevertheles, PFS may be not pre-
cise enough when evaluated retrospectively. At univariate 
analysis, there was a trend toward a longer OS for patients 
treated with platinum-based CT; at multivariate analysis, 
platinum-based CT was associated with a slight but signifi-
cantly decreased risk of death of 8% (p = 0.027). A trend 
was also observed for better OS in patients with good PS 
but with no influence at multivariate analysis. Although 
our study is likely to lack of statistical power, one possible 
TABLE 1.  Univariate and Multivariate Analyses of Factors Associated with Overall Survival
Univariate Multivariate
HR (CI 95%) pa HR (CI 95%) pa
Age (<62 vs. ≥62 yr) 1.23 (0.81–0.88) 0.350
Ethnicity (white vs. other) 0.96 (0.89–1.03) 0.249
Sex (men vs. women) 1.33 (0.83–2.14) 0.234
Tobacco-smoking status (current/former vs. never smoker) 0.95 (0.88–1.02) 0.179 0.92 (0.85–0.99) 0.040
Performance status (0−1 vs. 2−3) 1.04 (0.99–1.11) 0.149
Clinical stage (III vs. IV) 0.94 (0.88–1.01) 0.112 0.93(0.86–1.02) 0.057
Previous radical surgery (yes vs. no) 1.04 (0.99–1.10) 0.120 1.04 (0.98–1.11) 0.211
Chemotherapy (with vs. without platinum) 0.95 (0.90–1.00) 0.099 0.92 (0.85–0.99) 0.027
Control vs. progression at first-line CT 0.35 (0.22–0.57) <0.001 0.38 (0.21–0.59) <0.001
Data were obtained from 96 patients, with one missing datum.
aCox’s model, for multivariate analyses a backward procedure was used.
HR, hazard ratio; CI, confidence interval; CT, chemotherapy.
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explanation may be that factor “PS” is confounded by factor 
“cisplatin,” that is that cisplatin-based CT was delivered to 
patients with higher PS.
To conclude, our study indicates that SC is associated 
with poor prognosis, with a high rate of resistance to conven-
tional first-line CT. New therapeutic strategies are needed, 
possibly based on a better knowledge of the carcinogenesis of 
this rare tumor.
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